Breaking News

Sanofi Invests $425M in Flu Vaccine Manufacturing Facility

Newly licensed U.S. manufacturing facility to increase availability of Fluzone High-Dose Quadrivalent.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The U.S. FDA Center for Biologics Evaluation and Research (CBER) has granted approval to Sanofi Pasteur, the vaccines global business unit of Sanofi, for an additional influenza manufacturing facility located in Swiftwater, PA.   The newly completed $425 million investment in the facility expands production and distribution of Sanofi’s Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the U.S. and will create up to 200 additional manufacturing jobs. Commercializ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters